LEVEL JUMP
HEALTHCARE CORP.

INTERIM MANAGEMENT DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED MARCH 31, 2021.

(EXPRESSED IN CANADIAN DOLLARS)

Introduction

The following interim Management Discussion & Analysis ("Interim MD&A") of Leveljump Healthcare Corp. (formerly Leveljump UAS Corp.) ("Leveljump" or the "Company") for the three months ended March 31, 2021 has been prepared to provide material updates to the business operations, liquidity and capital resources of the Company since its last annual management discussion & analysis, being the Management Discussion & Analysis ("Annual MD&A") for the fiscal year ended December 31, 2020. This Interim MD&A does not provide a general update to the Annual MD&A, or reflect any non-material events since the date of the Annual MD&A.

This Interim MD&A has been prepared in compliance with section 2.2.1 of Form 51-102F1, in accordance with National Instrument 51-102 – Continuous Disclosure Obligations. This discussion should be read in conjunction with the Company's Annual MD&A, audited annual consolidated financial statements for the years ended December 31, 2020, and December 31, 2019, together with the notes thereto, and unaudited condensed interim consolidated financial statements for the three months ended March 31, 2021, together with the notes thereto. Results are reported in Canadian dollars, unless otherwise noted. The Company's unaudited condensed interim consolidated financial statements and the financial information contained in this Interim MD&A are prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations of the IFRS Interpretations Committee. The unaudited condensed interim consolidated financial statements have been prepared in accordance with International Standard 34, Interim Financial Reporting. Accordingly, information contained herein is presented as of May 31, 2021, unless otherwise indicated.

For the purposes of preparing this Interim MD&A, management, in conjunction with the Board of Directors (the "Board"), considers the materiality of information. Information is considered material if: (i) such information results in, or would reasonably be expected to result in, a significant change in the market price or value of Leveljump common shares; (ii) there is a substantial likelihood that a reasonable investor would consider it important in making an investment decision; or (iii) it would significantly alter the total mix of information available to investors. Management, in conjunction with the Board, evaluates materiality with reference to all relevant circumstances, including potential market sensitivity.

Additional information relating to the Company is available free of charge on the System for Electronic Document Analysis and Retrieval (SEDAR) website at **www.sedar.com.**

Cautionary Note Regarding Forward-Looking Statements

This Interim MD&A contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). These statements relate to future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates" or "believes", or variations of, or the negatives of, such words and phrases, or statements that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those anticipated in such forward-looking statements. The forward-looking statements in this Interim MD&A speak only as of the date of this Interim MD&A or as of the date specified in such statement. The following table outlines certain significant forward-looking statements contained in this Interim MD&A and provides the material assumptions used to develop such forward-looking statements and material risk factors that could cause actual results to differ materially from the forward-looking statements.

Inherent in forward-looking statements are risks, uncertainties and other factors beyond Leveljump's ability to predict or control. Please also make reference to those risk factors referenced in the "Risk Factors" section below. Readers are cautioned that the above chart does not contain an exhaustive list of the factors or assumptions that may affect the forward-looking statements, and that the assumptions underlying such statements may prove to be incorrect. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this Interim MD&A.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Leveljump's actual results, performance or achievements to be materially different from any of its future results, performance or achievements expressed or implied by forward-looking statements. All forward-looking statements herein are qualified by this cautionary statement. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements whether as a result of new information or future events or otherwise, except as may be required by law. If the Company does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements, unless required by law.

OVERALL PERFORMANCE

Summary of Business

Leveljump Healthcare Corp. was incorporated as Good2Go2 Corp., ("G2G2") under the Canada Business Corporations Act on March 21, 2019 ("Jump" or the "Company"). The Company's registered head office is 304-85 Scarsdale Rd., Toronto, ON, Canada M3B 2R2. The Company's website is www.leveljumphealthcare.com.

The Company's principal business activity is providing teleradiology services through its subsidiary Canadian Teleradiology Services, Inc. ("CTS"). Teleradiology is the process of providing remote off site reading of radiology scans such as CT, MRI, US, and X-ray. Hospital staff scan their emergency room patients, then page the Company's radiologist on call, who can then remotely view, via secured server, the images and diagnose the patient and provide a report back to the hospital.

Teleradiology is the next level of patient care that assists small urban and rural hospitals to connect with 24/7 care, ensuring their communities receive the same care that large urban hospitals receive.

Qualifying Transaction

Prior to December 2020, the Company was classified as a Capital Pool Corporation, as defined in Policy 2.4 of the TSX Venture Exchange (the "Exchange"). The principal business of the Company was the identification and evaluation of assets or businesses with a view to completing a Qualifying Transaction ("QT").

On December 4, 2020, the Company filed Articles of Amendment to consolidate its common shares at a ratio of 1:1.8 and changed its name to Leveljump Healthcare Corp., and on December 7, 2020, the Company closed its business combination involving CTS, as the QT of the Company (see Reverse Take-Over Note 5 in the Financial Statements for the year ended December 31, 2020).

Results for Q1 2021

The first quarter of 2021 was the strongest quarter in the Company's history. Demand for radiology reading services was high despite lockdown measures in Ontario. The Company was able to increase its revenue year over year for the first quarter by $276,854 or 21.6%. The Company believes this is a strong sign of the durability of the Company's business and evidence of the long-term demand for our services. While Company revenue increased, many hospitals had shut down elective procedures which does make up some of the Company's revenues, suggesting that as lockdowns are lifted and normal daily activities resume, revenue could increase further in the near future.

Industry Events and Trends

COVID-19 continues to have an impact on daily life in Ontario and there were continued lockdowns, as well as a reduction in healthcare services and elective procedures. A lot of focus in the news continues on the emergence and benefits of Telehealth operations (providing health care remotely). For the Company this is an ideal environment as the Company was already providing services in this manner to our hospital clients by allowing doctors to provide patient care without having to have the doctor attend at the hospital.

The Company believes that there is now more acceptance in the general population of telehealth work, than existed prior to the COVID-19 outbreak, and that ultimately this will enhance and improve our ability to acquire new contracts with hospitals. Key hospital decision makers such as department heads, radiologists, and hospital CEOs are now seeing the benefits of ensuring an uninterrupted flow of patient care via telehealth.

Management believes that hospitals and the healthcare industry will be looking for further ways to capitalize on the benefits of remote healthcare. This trend will continue at a fast pace. Healthcare companies that can capitalize on it will be served best.

As vaccination rates continue to climb, hospital procedures and regular doctor visits should increase due to the back log in the healthcare system from the past 12 months. We believe this may positively affect the Company as more medical imaging scans will be demanded.

Outlook for 2021

Management believes that the outlook for the Company for 2021 is strong based on a number of factors, including but not limited to, the increased demand for telehealth services, and the general population shifting to accept the idea of more telehealth services.

The Company has nearly no third-party debt and a strong cash position. These resources have positioned the Company well for its acquisition strategy.

The Company has adjusted its business model slightly, to increase its gross margins. This process began in the third quarter of 2020 and is accelerating and is expected to be fully implemented sometime in early 2022.

Our marketing activities are now expanding outside of Ontario and across Canada. The Company continues its onboarding of clients to its new software provider from our previous system, which will, once completed reduce operating costs and improve profit margins.
The Company plans to take advantage of organic growth and new client hospital contracts, while also looking at acquisitions that may be of strategic importance. Management believes that there is an opportunity for the Company to acquire profitable imaging centres in Canada in 2021.

The Company will also devote some time through its Leveljump Technologies subsidiary towards finding suitable products and services that fit within the Company business plans and that will impact the provision of healthcare in the future.

Financing and Share Issuances (See Notes 5, 11,12,13 in Financial Statements)

During the quarter ended March 31, 2021, the Company issued 169,444 common shares for cash of $30,500 through the exercise of warrants and options. The Company also issued 125,000 units for $37,500 in debts. Each unit consists of 1 common share and 1 warrant to purchase a share of common stock each at $0.50 with an expiry of 3 years.

LIQUIDITY AND CAPITAL RESOURCES

As at March 31, 2021, the Company had cash and cash equivalents in the amount of $ 604,791 (December 31, 2020 - $905,546). On March 31, 2021, the Company had working capital of $227,847 (December 31, 2020 - $486,130).

The Company's current assets as of March 31, 2021, excluding cash and cash equivalents were $893,003 (December 31, 2020: $1,011,146) which consisted of accounts receivable in the amount of $596,184 (December 31, 2020: $562,099), HST receivable of $93,296 (December 31, 2020: $83,020) and prepaid expenses and deposits totalling $203,523 (December 31, 2020: $366,028).

Current liabilities as at March 31, 2021, were $1,269,947 (December 31, 2020: $1,430,562) which were comprised of accounts payables and accrued liabilities of $888,682 (December 31, 2020: $1,006,949), current portion of lease liabilities $45,116 (December 31, 2020: $34,436), 'due to director' $336,150 (December 31, 2020: $340,114), and due to related party of $nil (December 31, 2020: $49,063).

The continuing operations of the Company are dependent upon its ability to raise adequate financing and to continue its operations in the future. For the quarter ended March 31,2021, the Company had a net loss and comprehensive loss of $708,597 and as at March 31, 2021 an accumulated deficit of $13,121,172. These uncertainties may cast significant doubt upon the Company's ability to continue as a going concern.

Although the Company has been successful in borrowing funds or raising equity capital in the past, there can be no assurance that the Company will have sufficient financing to meet its future capital requirements, or that additional financing will be available on terms acceptable to the Company in the future. The Company has and may continue to have capital requirements in excess of its currently available resources.

Covid-19

In March 2020, the World Health Organization declared a global pandemic related to the virus known as COVID-19. The expected impacts on global commerce are anticipated to be far reaching. To date there have been significant wide-spread stock market declines and the movement of people and goods has become restricted. As the Company has no material operating income or cash flows, it will be reliant on additional financing to fund ongoing operations and future acquisitions. An extended disruption may affect the Company's ability to obtain additional financing. The impact on the economy and the Company is not yet determinable; however, the Company's financial position, results of operations and cash flows in the current period have been impacted as patient volume has decreased resulting in decreased revenues for the Company. The Company's financial position, results of operations and cash flows in future periods may be materially affected. In particular, there may be heightened risk of liquidity or going concern uncertainty.

Liquidity Risk

Liquidity risk is the risk that the Company cannot meet a demand for cash or fund its obligations as they become due. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities as they become due. The Company is expanding and to meet its short and longer-term working capital requirements, the Company will attempt, if necessary, to secure further financing to ensure that those obligations are properly discharged. Operationally, the Company manages its liquidity by continuously monitoring forecasted and actual gross profit, expenses, and cash flows from operations. There have been no changes to this risk exposure from 2020.

The following tables illustrate the contractual maturities of financial liabilities for March 31, 2021 and December 31, 2020:

March 31, 2021	**Payments Due by Period $**				
	Total	Less than 1 year	1 – 3 years	4-5 Years	After 5 years
Accounts payable and accrued liabilities	888,682	888,682	-	-	-
Lease liabilities	53,074	45,116	7,958		
Due to director	336,150	336,150	-	-	-
Long term debt	60,000	60,000	-	-	-
TOTAL	1,337,906	1,329,948	7,958	-	-

December 31, 2020	Payments Due by Period $				
	Total	Less than 1 year	1 – 3 years	4-5 Years	After 5 years
Bank overdraft	-	-	-	-	-
Accounts payable and accrued liabilities	1,006,949	1,006,949	-	-	-
Lease liabilities	61,021	34,436	26,585	-	-
Due to director	340,114	340,114	-	-	-
Due to Related Party	49,063	49,063	-	-	-
Long term debt	60,000	-	60,000	-	-
TOTAL	1,517,147	1,430,562	86,585	-	-

CAPITAL RESOURCES

The Company defines capital as total shareholders' equity and long-term debt. The Company manages its capital structure, based on the funds available to the Company, to support the growth and development of its operations and bring new products to market and to ensure it continues as a going concern. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business. The Company will continue to assess new opportunities and seek to acquire an interest in growth situations if it feels there is sufficient economic potential and if it has adequate financial resources to do so.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There were no changes in the Company's approach to capital management during the quarter ended March 31, 2021 or the year ended December 31, 2020. The Company is not subject to externally imposed capital requirements.

OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any Off-Balance Sheet arrangements.

RELATED PARTY TRANSACTIONS AND BALANCES

Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. The following related party transactions were conducted in the normal course of operations and were made on an arm's length basis:

Period Ended December 31,	March 31, 2021	December 31, 2020
Key management compensation	$ 240,000	$ 477,600
Share swap	-	546,000
Share-based compensation	392,758	53,196
Interest expense on related party loan	-	6,079
	$ 632,758	**$ 1,082,875**

FIRST QUARTER RESULTS

Quarter Ended	March 31, 2021	March 31, 2020
Total revenue	$1,560,720	$1,283,866
Gross margin	305,955	251,608
Expenses	1,014,522	202,541
Net (loss) / income	(708,597)	49,067
Loss per share–basic and diluted	$(0.02)	$(306.67)

REVENUES

Teleradiology

For the three months ended March 31, 2021, the Company's teleradiology revenue increased by $284,168 to $1,536,531 compared to $1,252,363 in 2020.

Admin and Other

For the three months March 31, 2021, the Company's admin and sublease revenue was $24,190 which decreased by $7,313 compared to admin revenue for the same period in 2020 of $31,503. The Company had increased per study fees in the quarter but in Q1 2020 had a one time charge to a client for software integration which make Admin revenue appear to be lower in Q1 2021.

TOTAL REVENUE

Total revenue for the three months March 31, 2021, was up $276,854 to $1,560,720 compared to $1,283,866 for the three months ended March 31, 2020. The increase in total revenue is primarily a result of the increased teleradiology revenue.

COST OF SALES

Radiologist Reading Fees

For the three months ended March 31, 2021, the Company's reading fees totaled $1,211,502 higher by $210,717 compared to reading fees of $1,000,785 for the three months ended March 31, 2020. The increase in reading fees in the current three-month period is a result of the increased operations due to increased demand for the Company's services.

Medical Imaging Software

PACS costs for the three months ended March 31, 2021, was $26,728 compared medical images archiving costs of $16,620 for the three-month period ended March 31, 2020. This increase was related to an increase in patient volume requiring diagnostic interpretation during the first quarter for 2021.

Internet Connectivity

For the three months ended March 31, 2021, the Company's internet connectivity costs were $3,687 which decreased by $276 compared to the $3,963 for the same three-month period in fiscal 2020.

Medical Director Expenses

For the three months ended March 31, 2021, lead radiologist and medical director expenses were up by $1,960 to $12,850 compared to lead radiologist and medical director expenses of $10,890 for the three-month period ended March 31, 2020. The higher costs experienced during the three-month period ended March 31, 2020, was related to the increased operations of the Company.

TOTAL COST OF SALES

Total cost of sales during the first quarter in 2021 including reading fees, PACS, internet connectivity and, radiologists and medical director expenses were $1,254,766 compared to $1,032,257. Higher cost of sales experienced during the first quarter in 2021, was primarily a result of increased operations due to higher demand for the Company's services.

GROSS PROFIT

As a result of the above revenues net of cost of sales, the Company's gross margin increased by $54,347 to $305,955 for the three-month period ending March 31, 2021, versus gross margin of $251,608 for the same three-month period in 2020.

EXPENSES

Stock Based Compensation

For the three months ended March 31, 2021, the Company recorded stock-based compensation for $392,758. No stock-based compensation was recorded for the same period in 2020. The stock-based compensation during the quarter was for amortization of options issued to management and directors in 2020.

Salaries and Wages

For the three months ended March 31, 2021, the Company recorded salaries and wages of $279,714 compared to $105,216 for the same three-month period ended March 31, 2020. The increase in salaries recorded in the 1st quarter of fiscal 2021, was a result of increased salaries for the Company's executives.

Advertising and Marketing

For the three months ended March 31, 2021, the Company recorded advertising and marketing expenses for $175,257. No marketing and advertising expenses were recorded for the same period in 2020. The expenses occurred in the quarter were for contracts signed in 2020 for investor outreach and institutional outreach related to the Company's qualifying transaction and listing on the TSXV exchange.

Professional Fees

For the three months ended March 31, 2021, the Company recorded professional fees of $95,495 up considerably by $81,650 compared to $13,845 for the three months ended March 31, 2020. The increase in professional fees for the three months ended March 31, 2021, was primarily attributed to increased consulting and legal fees in the first quarter because of the Company's investigation of possible acquisitions.

General and Administrative

General and administrative costs totaled $33,917 up $18,592 for the three months ended March 31, 2021, compared to general and administrative costs of $15,325 for the same three-month period in 2020. The Company experienced an increase in general and administrative costs during the current period in fiscal 2020, because of the change in the Company's PACS imaging software systems, additional dues and subscriptions for new computer services.

Insurance

Insurance expense for the three months ended March 31, 2021, increased significantly by $17,333 to $22,458 when compared to $5,125 for the same period in 2020. The increase was a result of the Company obtaining a directors and officers insurance plan.

Depreciation and Amortization

For the three months ended March 31, 2021, depreciation and amortization costs consistent at $8,183. There was no change in depreciation and amortization expense for the same period from 2020 to 2021.

Premises Rental

For the three months ended March 31, 2021, the Company incurred premises rental costs of $2,811 compared to premises rental costs of $2,291 for the three months ended March 31, 2020.

TOTAL OPERATING EXPENSES

Total expenses for the three months ended March 31, 2021, were $1,010,591, higher by $860,607 when compared to total expenses of $149,984 for the three months ended March 31, 2020. The primary factors relating to the increase in total expenses during the first quarter of 2021 were due to the stock based compensation expenses of $392,758, and advertising and marketing expense of $175,257, both of which were not present in the first quarter of 2020. The increase in professional fees and insurance also increased the total operating expenses for the first quarter of 2021.

OTHER EXPENSES

Royalty Expense

There were no royalty expense for the three months ended March 31, 2021 compared to $32,804 for the three months ended March 31, 2020. The royalty was bought out in 2020 and the Company no longer has an obligations under this arrangement.

Finance Costs

For the three months ended March 31, 2021, the Company recorded finance costs of $3,333 which was down by $15,340 versus finance costs of $18,673 for the three-month period ended March 31, 2020. The decrease in finance costs during the first quarter of 2021 was primarily related to the iCapital loan repayment and no more interest due on this loan.

Other Miscellaneous Expenses

For the first three months ended March 31, 2021 the Company had recorded $628 in miscellaneous expenses. In 2020 for the first quarter, miscellaneous expenses were $nil.

Foreign Exchange Loss

No foreign exchange loss was recorded in the first quarter of 2021, compared to the $1,080 which was recorded for the same period in 2020.

TOTAL EXPENSES

Total expenses for the three months ended March 31, 2021, were $1,014,552 higher by $812,011 compared to $202,541 for the three-month period ended March 31, 2020. The increase in total expenses for the three-month period ended March 31, 2021 was primary related to the stock-based compensation, and advertising and marketing, along with professional fees, general and administrative costs, and insurance expense.

NET LOSS AND COMPREHENSIVE LOSS

As a result of the above factors, the net loss and comprehensive loss for the three months ended March 31, 2021, was $708,597, compared to a net income and comprehensive income of $49,067 for the three months ended March 31, 2020, a difference of $757,664.

LOSS PER SHARE – BASIC AND DILUTED

The loss per share-basic and diluted for the three months ended March 31, 2021 was $0.02 versus the loss per share-basic and diluted of $306.67 for the comparable three-month period in 2020.

PROPOSED TRANSACTIONS

The Company does not have any proposed transactions.

CHANGES IN ACCOUNTING POLICIES

The Company had no accounting policy changes in the quarter and none are planned for 2021.

FINANCIAL INSTRUMENTS AND OTHER INSTRUMENTS

On April 17, 2020, the Company entered a CEBA loan with TD Canada Trust for $40,000. The initial term of the loan is until December 31, 2022 and if paid in full by that time no interest will be due under the loan and the Company will only be required to pay back $30,000. If the loan is not paid in full by December 31, 2022 it will convert into a 3- year term loan with interest at 5%. On December 30, 2020, the Company received the CEBA extension loan of $20,000 so the full CEBA loan now has a balance of $60,000 and if paid back by December 31, 2022 only $40,000 will need to be repaid. This loan was repaid in May 2021.

Credit risk

Credit risk is the risk of loss associated with a counter-party's inability to fulfill its payment obligations. The Company's cash and accounts receivable are exposed to credit risk. Jump's cash is held with a major Canadian-based financial institution and as such management believes that the associated credit risk is remote.

Account receivables represents revenue earned from services rendered to hospitals. The Company has adopted a credit policy under which each new customer is analyzed individually for creditworthiness before the Company’s standard payment terms and conditions are offered.

The Company’s trade receivables are concentrated among customers in the healthcare industry, which may be affected by adverse government policy impacting that industry. As of December 31, 2020, two customers accounted for greater than 69% of the Company’s trade receivable balance.

There have been no changes to this risk exposure from 2019.

The Company's maximum exposure to credit risk as of March 31, 2021 and December 31, 2020, was as follows:

	December 31, 2020	December 31, 2020
Cash and cash equivalents	$ 604,791	$ 905,546
Accounts receivable	596,184	562,099
Prepaid expenses and deposits	203,523	366,028
Total	**$ 1,833,673**	**$ 1,833,673**

SHARE CAPITAL AND RESERVES

Authorized Share Capital

As at the date of filing this report the Company had 50,658,844 common shares outstanding. There are no other approved classes of shares for the Company.

Stock Options

As at the date of filing this report the Company had 4,331,112 options issued and outstanding, of which 1,227,805 are vested and exercisable into shares of common stock. (see Interim Financial Statements Note 10)

Warrants

As at the date of filing this report the Company had 20,186,622 common share purchase warrants issued and outstanding. (see Interim Financial Statements Note 11)

Broker Options

As at the date of filing this report the Company had 696,040 broker options issued and outstanding, each convertible into a unit consisting of 1 common share and 1 common share purchase warrant. (see Interim Financial Statements Note 12)